Today's News

• Get these news in RSS

• Neurogenetic Pharmaceuticals Announces Studies Showing Its Proprietary Compound Reduces Brain Plaques Associated with Alzheimer?s Disease Today, 12:13 PM (GMT+1)

  In the Sept. 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer?s disease (AD) in a transgenic mouse model. The study further demonstrates that following chronic treatment with the gamma secretas

• Onyx Pharmaceuticals Announces Carfilzomib Development and Commercialization Agreement with Ono Pharmaceutical for Japan Wed, 12:00 (GMT+1)

  Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd. to develop and commercialize two compounds from Onyx?s proteasome inhibitor development program, carfilzomib and ONX 0912. Under the terms of the agreement, Ono has exclusive rights to develop and commercialize

• Rhythm Closes $40 Million Series A Financing Wed, 12:00 (GMT+1)

  Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that it has completed its Series A financing, increasing the total funding raised to $40 million. The first closing on the previously announced $21 million Series A financing was led by MPM Capital (MPM) and New Enterprise Associates (NEA). Third

• Progenics Pharmaceuticals Initiates Oral Methylnaltrexone Phase 3 Trial in Patients with Chronic Non-Cancer Pain Wed, 12:00 (GMT+1)

  Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral me

• Other News

• Zyngenia Raises $15 Million in Series A Extension Financing Wed, 12:00 (GMT+1)

• DARA Announces Analytical Results in Efficacy and Dose Response of KRN5500 in Patients with Chemotherapy Induced Peripheral Neuropathy and Advanced Cancer Wed, 12:00 (GMT+1)

• Hemispherx Biopharma to Present New Retrovirus (XMRV) Data at 1st International Workshop on XMRV and Chronic Fatigue Syndrome (CFS) Wed, 12:00 (GMT+1)